NOW AVAILABLE: Read + download the #ASGCT2025 abstracts! Check out our largest-ever collection of CGT research and register to join us next month!
In Q3, Tecelra was approved for adults with metastatic synovial sarcoma, newly initiated gene therapy trials increased for non-oncology indications, and seed and Series A funding nearly doubled.
The third quarterly report of 2024 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
Highlights from this issue include:
Tecelra became the first gene therapy approved for adults with metastatic synovial sarcoma and the first FDA-approved T cell receptor (TCR) gene therapy
The field steadily diversified, with data showing 51% of newly initiated gene therapy trials are for non-oncology indications, up from 39% year-over-year
Seed and Series A funding nearly doubled to $484 million
Download the full report
May 13-17, 2025 | New Orleans
© 2000-2025 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico